Derya Şahin

Derya Şahin

Auto-generated profile, based on publicly available information

Derya Şahin

Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
HBHikmettullah Batgi̇
Hikmettullah Batgi̇
SBSemih Başcı
Semih Başcı
MDMehmet Sinan Dal
Mehmet Sinan Dal
MÇMerih Kizil Çakar
Merih Kizil Çakar
BUBahar Uncu Ulu
Bahar Uncu Ulu
FAFevzi Altuntaş
Fevzi Altuntaş
GDP (gemcitabine, dexamethasone and cisplatin) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobilization. Data of 69 relapsed and refractory Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients who received GDP/R-GDP as salvage chemotherapy in our center between July 2014 and January 2020 were retrospectively evaluated. After the evaluation of response, 52 patients had a chemosensitive disease and underwent mobilization with GDP/R-GDP plus G-CSF (granulocyte colony-stimulating factor). Collected CD34+ stem cells and related parameters were compared in terms of diagnosis of HL and NHL, early and late stage, patients who did not receive RT and those who received RT, and patients aged under 60 and over 60. On the 15th day on average (range 11?20), median 8.7 × 106 /kg (4.1 - 41.5) CD34+ stem cells were collected in 51 (98%) of our 52 chemosensitive patients and 1 (2%) patients failed to mobilize. We observed acceptable hematological and non-hematological toxicity. The targeted amount of 2 × 106 /kg CD34+ stem cells was attained by 98% (n: 51) patients, and all of them underwent autologous stem cell transplantation. Moreover, low toxicity profiles provide outpatient utilization option clinics with close follow-up and adequate supportive care. We suggest that GDP/R-GDP plus G-CSF can be used as an effective chemotherapy regimen for mobilizing CD34+ stem cells from peripheral blood in relapsed and refractory lymphoma patients due to low toxicity, effective tumor reduction, and successful stem cell mobilization. It can also be assumed that the GDP mobilization regimen may be more effective, especially in patients with early-stage disease and in HL patients.

1 November 2021 in Leukemia Research
Verified
Journal Article
Closed access
BUBahar Uncu Ulu
Bahar Uncu Ulu
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
MBMehmet Bakirtas
Mehmet Bakirtas
DŞDerya Şahin
Derya Şahin
FAFevzi Altuntaş
Fevzi Altuntaş

1 June 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
BUBahar Uncu Ulu
Bahar Uncu Ulu
MBMehmet Bakirtas
Mehmet Bakirtas
AKAli Kılınç
Ali Kılınç
FAFevzi Altuntaş
Fevzi Altuntaş

1 June 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
MBMehmet Bakirtas
Mehmet Bakirtas
BUBahar Uncu Ulu
Bahar Uncu Ulu
AKAli Kılınç
Ali Kılınç
FAFevzi Altuntaş
Fevzi Altuntaş

18 June 2020 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
TYTuğçe Nur YİĞENOĞLU
Tuğçe Nur YİĞENOĞLU
SBSemih Başcı
Semih Başcı
DŞDerya Şahi̇n
Derya Şahi̇n
MBMehmet Bakirtas
Mehmet Bakirtas
AKAli Kilinc
Ali Kilinc
FAFevzi Altuntaş
Fevzi Altuntaş
Introduction: It has been shown that there is an increase in the number of progenitor cells in the bone marrow after smoking cessation. Adequate number of stem cells should be given to the patients to provide sustained engraftment after allogeneic stem cell transplantation. Therefore, determining the factors affecting the success of peripheral stem cell mobilization in allogenic donors is very important. In this study, we aimed to investigate the effect of smoking on the amount of stem cells collected after peripheral blood stem cell mobilization in allogeneic donors.Material and Method: The data of 157 allogeneic donors who were performed peripheral stem cell mobilization in our center were analyzed retrospectively. The donors were divided into 2 groups:active smokers (n:80) and non-smokers (n:77). Smokers were divided into two groups as donors who smoked <15 cigarette pack year and those who smoked ≥15 cigarette pack year.Results: The median CD34+ cell count in the peripheral blood on the 5th day before apheresis was found to be significantly lower in smokers than in non-smokers (p=0.001*). Compared to the donors who smoked <15 cigarette pack year, the median CD34+ cell count in the peripheral blood on the 5th day before apheresis was significantly lower in the donors who smoked ≥15 cigarette pack year (p=0.009*).Conclusion:During the allogeneic stem cell donor assessment, donors should be questioned for their smoking history. Smoking should be considered as a negative risk factor for peripheral stem cell mobilization, especially in the donors who smoke ≥15 cigarette pack year.

18 June 2021 in Medical Laboratory Technology Journal
Verified
Journal Article
Open access
PDF file
BUBahar Uncu Ulu
Bahar Uncu Ulu
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
MBMehmet Bakirtas
Mehmet Bakirtas
DŞDerya Şahin
Derya Şahin
FAFevzi Altuntaş
Fevzi Altuntaş
The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront autologous stem cell transplantation (ASCT), has been accepted the standard treatment approach for newly diagnosed fit MM patients. We aimed to search the real-life data, the efficacy and safety of upfront ASCT following induction in patients with MM over 60 years old retrospectively. The data of MM patients who were ≥60 years old during autologous stem cell transplantation and treated at our center between 2010 and 2018 retrospectively analyzed. The study results were 63 patients included at the age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, and the median overall survival (OS) was 28.15±5 months. According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in the ≥70 age group. A significant relationship between the quantity of infused CD34+ stem cells and PFS and OS (p:0.05 and p<0.00, respectively). Our study indicated that a high dose (200 mg/m2 ) melphalan could safely be used in the physically fit patients at the ages of 60-69, and a reduced amount (140 mg/m2 ) would be the appropriate dose for the patients over 70. The quantity of infused CD34+ stem cells affect elderly MM patients; mobilization dynamics are also important factors for elderly myeloma. Age itself should not consider a barrier to ASCT, and a comprehensive geriatric evaluation should perform on elderly patients